Antisense oligonucleotide suppression of non-deletion DMD causing mutations

反义寡核苷酸抑制非缺失 DMD 引起的突变

基本信息

  • 批准号:
    7800953
  • 负责人:
  • 金额:
    $ 22.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-01-01 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle-wasting disorder caused by protein truncating mutations in the dystrophin gene. Antisense oligomer induced removal of an exon carrying a nonsense mutation, or exons flanking frame-shifting deletions, the most common type of DMD mutation, has been shown to generate an in-frame message and an internally deleted, but functional protein. Becker muscular dystrophy (BMD) is an allelic disorder typically caused by in-frame deletions of one or more exons, most commonly in the first two thirds of the gene. The severity of BMD varies from borderline DMD to asymptomatic, and the dystrophin genes in mildly affected BMD patients provide an indication of functional exon combinations. At least one third of DMD cases result from duplications, micro-insertions/deletions and single base changes that alter splice site recognition or cause premature termination of translation. This project will address the design and application of antisense oligomers for induced exon skipping, for those DMD cases caused by non-deletion mutations. Patient cell lines will be transfected with test compounds and exon skipping assessed. Exon skipping strategies will be modified to maximize induced dystrophin quality and quantity, as permitted by the context of each particular dystrophin gene lesion. The specific aims are to: 7 Optimise antisense oligomers to remove exons carrying sequence variations (disease-causing or neutral polymorphims) that would otherwise compromise exon skipping. 7 Develop exon skipping strategies appropriate to DMD cases caused by pseudo-exon incorporation or duplications of one or more exons. 7 Develop transient animal models to identify functionally significant dystrophin domains, according to exon boundaries, to facilitate design of optimal exon skipping strategies. PUBLIC HEALTH RELEVANCE: Duchenne muscular dystrophy is a relentlessly progressive, fatal disease for which there is no effective treatment. Specific exon removal has the potential to greatly reduce the severity of DMD, and restoration of dystrophin expression, even of partial function in a DMD patient is expected to result in a BMD-like phenotype, and reduce morbidity and extend life expectancy. This application seeks to develop personalised exon skipping therapies for the one third of DMD patients who have non-deletion mutations. Exon skipping should be made available to all patients who could benefit, not only those with the more common exon deletion mutations.
描述(由申请人提供): 杜氏肌营养不良症(DMD)是一种致命的X-连锁肌肉萎缩性疾病引起的蛋白质截短突变的肌营养不良基因。反义寡聚体诱导去除携带无义突变的外显子,或侧翼移码缺失的外显子,最常见的DMD突变类型,已显示产生框内信息和内部缺失但功能性蛋白。贝克肌营养不良症(BMD)是一种等位基因疾病,通常由一个或多个外显子的框内缺失引起,最常见的是基因的前三分之二。BMD的严重程度从临界DMD到无症状不等,轻度受累BMD患者的肌营养不良蛋白基因提供了功能性外显子组合的指示。至少三分之一的DMD病例是由重复、微插入/缺失和单碱基变化引起的,这些变化改变了剪接位点识别或导致翻译过早终止。本计画将针对非缺失突变所引起的DMD病例,设计并应用反义寡聚物来诱导外显子跳读。将用测试化合物转染患者细胞系并评估外显子跳跃。外显子跳跃策略将被修改以最大化诱导的肌营养不良蛋白的质量和数量,如每个特定肌营养不良蛋白基因病变的背景所允许的。具体目标是:7优化反义寡聚体,以去除携带序列变异(致病或中性多态性)的外显子,否则会损害外显子跳跃。7开发适合于由假外显子掺入或一个或多个外显子重复引起的DMD病例的外显子跳跃策略。7建立瞬时动物模型,根据外显子边界识别功能重要的肌营养不良蛋白结构域,以促进最佳外显子跳跃策略的设计。 公共卫生相关性: 杜氏肌营养不良症是一种无情的渐进性,致命的疾病,没有有效的治疗。特异性外显子去除具有极大地降低DMD的严重性的潜力,并且预期DMD患者中肌养蛋白表达的恢复,甚至部分功能的恢复将导致BMD样表型,并且降低发病率和延长预期寿命。该申请旨在为三分之一具有非缺失突变的DMD患者开发个性化外显子跳跃疗法。外显子跳读应该提供给所有可能受益的患者,而不仅仅是那些更常见的外显子缺失突变的患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN D WILTON其他文献

STEPHEN D WILTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN D WILTON', 18)}}的其他基金

Antisense oligonucleotide suppression of non-deletion DMD causing mutations
反义寡核苷酸抑制非缺失 DMD 引起的突变
  • 批准号:
    8278448
  • 财政年份:
    2004
  • 资助金额:
    $ 22.4万
  • 项目类别:
Antisense oligonucleotide suppression of DMD
DMD 反义寡核苷酸抑制
  • 批准号:
    6723427
  • 财政年份:
    2004
  • 资助金额:
    $ 22.4万
  • 项目类别:
Antisense oligonucleotide suppression of DMD
DMD 反义寡核苷酸抑制
  • 批准号:
    6837699
  • 财政年份:
    2004
  • 资助金额:
    $ 22.4万
  • 项目类别:
Antisense oligonucleotide suppression of Duchenne Muscular Dystrophy
杜氏肌营养不良症的反义寡核苷酸抑制
  • 批准号:
    7210764
  • 财政年份:
    2004
  • 资助金额:
    $ 22.4万
  • 项目类别:
Antisense oligonucleotide suppression of DMD
DMD 反义寡核苷酸抑制
  • 批准号:
    7025814
  • 财政年份:
    2004
  • 资助金额:
    $ 22.4万
  • 项目类别:
Antisense oligonucleotide suppression of non-deletion DMD causing mutations
反义寡核苷酸抑制非缺失 DMD 引起的突变
  • 批准号:
    8044694
  • 财政年份:
    2004
  • 资助金额:
    $ 22.4万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.4万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了